glp 1 mimetics Table 2 from Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Drug Class Review It Is a Huge Market.

MayJune 2023

Novo will have a nice heads up on the manufacturing challenge because it already markets Rybelsus, which became the first oral treatment for type 2 diabetes when it received FDA approval in 2019

May 16, 2026- A new study from Veterans Affairs, published last month in JAMA Network Open, adds further weight to a growing body of evidence connecting GLP-1 medications to a heightened risk of non-arteritic anterior ischemic optic neuropathy, or NAION a condition in which damage to the optic nerve can cause symptoms ranging from mild vision disturbances to permanent blindness

Final Thoughts GLP-1 medications can be powerful tools for improving health